Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

Wester, D. W.; Steele, Richard T.; Rinehart, Donald E.; DesChane, J.R.; Carson, Katharine J.; Rapko, Brian M.; Tenforde, T.S.

doi:10.1016/s0969-8043(03)00151-9

Cited by 18 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…60 Strontium-90 is one of the major fission products of 235 U with fission yield of 5.93% and can be isolated from aqueous nuclear fuel reprocessing high-level liquid waste solutions. [62][63][64][65][66][67][68] Purity requirements for 90 Sr for availing medically useful 90 Y are very high and extensive quality controls are essential.…”

Section: Production Of Radionuclides Currently Used In Prrtmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy: An Overview

Dash

Chakraborty

Pillai³

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

101

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.

show abstract

Section: Production Of Radionuclides Currently Used In Prrtmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy: An Overview

Dash

Chakraborty

Pillai³

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

101

View full text Add to dashboard Cite

show abstract

“…There is a potentially nearly unlimited availability of 90 Y, since 90 Sr is a major fission product available in large quantities from spent fuel . The ion exchange or extraction is practically used as the production route of 90 Y .…”

Section: Radiometals For Theranostic Applicationsmentioning

confidence: 99%

“…There is a potentially nearly unlimited availability of 90 Y, since 90 Sr is a major fission product available in large quantities from spent fuel. 56,57 The ion exchange or extraction is practically used as the production route of 90 Y. 58 Several generator systems have been reported, utilizing precipitation, cation exchange, extraction chromatography methods, and electrochemical separation.…”

Section: Gamentioning

confidence: 99%

“…135,136 Natural Ni target foils or targets prepared with enriched 58 Ni electroplated on copper, gold, or silver backings are irradiated with proton energies of 10 to 15 MeV. 130,135,137 While the cross section for 55 Co is higher at higher energies, 138 typically the irradiation of targets is carried out at lower proton energies to minimize the production of 57 Co, which is produced either directly by the 60 Ni(p,α) 57 Co reaction when using Ni targets of natural composition or from the decay of 57 Ni that is produced via the 58 Ni(p,pn) 57 Ni reaction. The purification procedures for 55 Co produced using Ni targets are typically similar to those employed for 64 Cu.…”

Section: Comentioning

confidence: 99%

See 1 more Smart Citation

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.

show abstract

“…in increasing demand, mostly because of its convenient production from the long half-lived 90 Sr [2,3] by methods like precipitation [4], extraction [5,6], ion exchange chromatography [7] and electrochemical separation [3], among many others.…”

Section: Introductionmentioning

confidence: 99%

An adapted purification procedure to improve the quality of ⁹⁰Y for clinical use

Castillo¹,

Isaac‐Olivé²,

Casanova‐González³

et al. 2009

Radiochimica Acta

View full text Add to dashboard Cite

90 Y separation / 90 Sr/ 90 Y chromatographic generator / 90 Y for clinical use / 90 Y purification / Ion exchange chromatography Summary. There is an increasing interest for 90 Y for radionuclide therapy. However, radioimmunotherapy, one of the most important applications for 90 Y, demands a very high purity product. Obtaining a high quality 90 Y is difficult not only because of the complex and time consuming production schemes but also because of the quality control which has challenging tasks like the determination of 90 Sr at very low concentrations. The present paper investigates a reported purification procedure for the removal of stable metal trace contaminants from an 90 Y solution, seeking for its potential use in the elimination of the radioactive contaminant 90 Sr and its fast determination. For this purpose a washing step with HNO 3 acid is introduced to elute 90 Sr, the order of each acid solution is rearranged to reduce the potential contaminants present in acids and the size of the column is reduced to further optimize the procedure. As a result, an improved purification method is obtained, which allows the removal of both trace metal contaminants and 90 Sr from an 90 Y solution and the measurement of 90 Sr/ 90 Y ratios of the order of 10 −7 , which are well below the established pharmacopeia limit of 2 × 10 −5 .

show abstract

Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

Cited by 18 publications

References 11 publications

Peptide Receptor Radionuclide Therapy: An Overview

Peptide Receptor Radionuclide Therapy: An Overview

Radiometals for imaging and theranostics, current production, and future perspectives

An adapted purification procedure to improve the quality of ⁹⁰Y for clinical use

Contact Info

Product

Resources

About

Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

Cited by 18 publications

References 11 publications

Peptide Receptor Radionuclide Therapy: An Overview

Peptide Receptor Radionuclide Therapy: An Overview

Radiometals for imaging and theranostics, current production, and future perspectives

An adapted purification procedure to improve the quality of 90Y for clinical use

Contact Info

Product

Resources

About

An adapted purification procedure to improve the quality of ⁹⁰Y for clinical use